What is Ubretid used for?

Ubretid is indicated for Acute cystitis, Difficulty passing urine, Myasthenia gravis.

Ubretid is developed by Torii Pharmaceuticals.

What development phase is Ubretid in?

Ubretid is FDA-approved (marketed).

What is the generic name of Ubretid?

DISTIGMINE is the generic (nonproprietary) name of Ubretid.

Last reviewed 2026-04-20 · How we verify

Ubretid (DISTIGMINE)

Torii Pharmaceuticals · FDA-approved active Small molecule Quality 29/100

At a glance

Generic name	DISTIGMINE
Sponsor	Torii Pharmaceuticals
Drug class	distigmine
Target	Acetylcholinesterase
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	FDA-approved

Approved indications

Acute cystitis
Difficulty passing urine
Myasthenia gravis

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ubretid CI brief — competitive landscape report
Ubretid updates RSS · CI watch RSS
Torii Pharmaceuticals portfolio CI